The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Music
  • Financial
  • Construction
  • Manufacturing

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • Automation, innovation in healthcare processes featured at international conference in Atlanta
  • Secondesk Launches Powerful AI Tutor That Speaks 20+ Languages
  • A High-Velocity Growth Story Emerges in Marine and Luxury Markets
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • Mark Schork Selected As 'Board Observer' By Philadelphia Bar Foundation
  • Collective Meditation for Peace - Free Global Event
  • Daniel Kaufman Launches a Vertically Integrated Real Estate and Investment Platform
  • Long Long Tales: Bilingual Cartoon Series on Youtube Celebrating Chinese New Year
  • MAX Illumination Redefines Cabinet Displays with New Edge-Lit LED Technology

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • $10 Price Target in Think Equity Report Supported by Inventory Financing Floorplan Boot to $60 Million for 2026 Sales Growth in Pre-Owned Boats: $OTH
  • Poolvillas Expands Local Presence on the Costa Blanca with New Offices in Moraira and Denia – Over 30 Years of Expertise Now Even Closer to Guests
  • Radarsign Redefines Crosswalk Safety with Launch of CrossCommand™ RRFB Crosswalk
  • OpenSSL Corporation Opens 2026 Advisory Committees' Elections: Shape the Future!
  • Steve Everett Jr. Named President of L.T. Hampel Corporation
  • Acuvance Acquires ROI Healthcare Solutions, Building a Dedicated Healthcare ERP Practice
  • Max Tucci Award-Winning Media Powerhouse Launches New Podcast —Executive Produced by Emmy-Winning Daytime Icons Suzanne Bass & Fran Brescia Coniglio
  • MILBERT.ai Brings Real Time Session Defense to Google Workspace and Google Cloud
  • Appliance Outlet Caps Off a Record-Setting 2025 Nationwide, Gears Up for Even Greater Growth in 2026
  • Perry County Real Estate Agency Partners with Internet Marketing Company
  • Philadelphia HVAC Companies Were Not Created Equal
  • Home Prices Just Hit 5X Median Income — So Americans Are Buying Businesses Instead of Houses
  • Briggs Auction's Jan. 30 online Fine Estates Auction features artworks by Hans Hoffman, Hans Coper, Lucie Rie, Loet Vanderveen
  • Peak Exteriors LLC to Open First Office in East Berlin in 2026
  • CCHR White Paper Urges Government Crackdown on Troubled Teen and For-Profit Psychiatric Facilities
  • MoMojo Records signs Billy Thompson
  • Still Searching for the Perfect Valentine's Gift? Lick Personal Oils Offers Romantic, Experience-Driven Alternatives to Traditional Presents
  • Jaeigh Gallagher Records: Redefining Independent Music and Global Pop Culture
  • Boston Industrial Solutions' BPA Certified BX Series Raises the Bar for Pad Printing Inks
  • Boston Corporate Coach™ Sets Global Standard for Executive Chauffeur Services Across 680 Cities

Popular on PennZone

  • Neurosurgeon Chengyuan Wu, MD, MSBmE, Joins the Actuated Medical Advisory Board - 233
  • Together We Dance Foundation Announces Transformational Support from NAC Have a Heart Foundation
  • Lacy Hendricks Earns Prestigious MPM® Designation from NARPM®
  • Robert DeMaio, Phinge Founder & CEO, Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
  • Appliance EMT Expands Professional Appliance Repair Services to Hartford, Connecticut
  • Pawprint Oxygen Turns Pet Safety Viral With "Pets Live Here" Window Decals — Helping First Responders Save Lives
  • Guests Can Save 25 Percent Off Last Minute Bookings at KeysCaribbean's Village at Hawks Cay Villas
  • TheOneLofi2: New Home for Chill Lo-Fi Hip Hop Beats Launches on YouTube
  • Phinge Founder & CEO Robert DeMaio Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
  • Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Birmingham SE / Liberty Park

Similar on PennZone

  • SNS Research Launches SNS Market Intelligence Platform for visual market intelligence for pharma
  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
  • AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us